A clinical laboratory and its owner and chief executive officer have agreed to pay $13.25 million to resolve False Claims Act allegations involving illegal kickbacks and medically unnecessary laboratory testing, US Attorney Philip R. Sellinger announced. RDx Bioscience Inc. (RDx), of Kenilworth, New Jersey, and its owner and chief executive officer, Eric Leykin, of Brooklyn, New York, agreed to pay the United States $10.32 million and will pay an additional $2.93 million to the state of New Jersey. RDx and Leykin have agreed to cooperate with the Department of Justice’s investigations of, and litigation against, other participants in the alleged schemes.
